Massive Bio
PrivateLast Round
Corporate Funding
Jan 15, 2025
Total Funding Raised
$38.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Massive Bio operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series B round in December 2022.
Massive Bio is a health technology company that provides an artificial intelligence-driven platform designed to connect cancer patients to biopharmaceutical clinical trials.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical AI, Healthcare Analytics, Biotechnology, NLP & Conversational AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Massive Bio Comparables
Compare Massive Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Leal Health | 84% | |
| TriNetX | 81% | |
| Paradigm Health | 81% |
For institutional investors. Book with your work email.
Massive Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Jan 15, 2025 | ||||
| Series B | Dec 15, 2022 | ||||
| Series B | Jun 3, 2022 | ||||
| Grant | Dec 17, 2020 | ||||
| Series A | Nov 3, 2020 | ||||
Seed | May 2, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Massive Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| UL Ventures | Seed |
| International Finance Corporation | Series B |
| KFW DEG | Series B |
| 500 Global | Seed |
| SiteGround Capital | Series B |
| Cavendish Impact Foundation | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 23, 2026
Ranked #4 on Fast Company's Startup 100 list for Turkey.
- Apr 29, 2026
Broadens access to clinical trials through collaboration.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 2, 2026
Massive Bio, Inc. and Glow Oncology announce a partnership in Florida on Nov 2nd '26 to connect patients and caregivers with clinical trial information, matching, and navigation support.
- recognized_asSep 30, 2026
Massive Bio, Inc. has been recognized by TIME as one of the top HealthTech companies in the AI and Data Analytics category on TIME’s World’s Top HealthTech Companies 2026 list, produced in collaboration with Statista.
- recognized_asSep 30, 2026
TIME recognizes Massive Bio, Inc. in its World's Top HealthTech Companies 2026 list in the AI & Data Analytics category, produced with Statista and ranking 500 companies worldwide based on financial performance, reputation, and online engagement.
- is_developingSep 30, 2026
Massive Bio, Inc. aims to develop longitudinal patient digital twins and oncology world models to research disease trajectories and treatment pathways, with potential applications in predictive modeling, simulation, and drug development.
- expands_offices_inSep 17, 2026
On Sep 17th '26, Massive Bio, Inc. expands its Asia footprint into South Korea by appointing Intralink to build partnerships with hospitals, diagnostic laboratories, and oncologists.
For institutional investors. Book with your work email.
Massive Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Massive Bio's valuation, stock price, and market status.
Is Massive Bio a public or private company?
Massive Bio is a private company.
What is the current stock price of Massive Bio?
Massive Bio is a private company, so its shares have no public market price. Caplight tracks Massive Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Massive Bio worth (valuation)?
Valuation information for Massive Bio is not publicly available.
Can I buy Massive Bio stock?
Massive Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Massive Bio's last funding round?
Massive Bio's most recent funding round was Corporate Funding on January 15, 2025.
Who are the main investors in Massive Bio?
Key investors in Massive Bio include Revo Capital.
Will Massive Bio IPO soon?
No public IPO plans have been announced for Massive Bio.
How can I track Massive Bio secondary market activity?
Caplight tracks bids, offers, and trades in Massive Bio's shares on secondary markets.